WEE1 and hepatocellular carcinoma: Sorafenib is a protein kinase inhibitor that obtained FDA approval for the treatment of advanced HCC in late 2007, and for a long time it was the only systemic agent with proven clinical efficacy in patients with unresectable HCC [94].